Yale University: Melanoma trials

The registry lists 12 Melanoma studies with Yale University as lead sponsor. 0 are open to participants now and 7 have results posted.

Early Phase 1 2Phase 1 4Phase 2 7(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell CarcinomaTerminatedNCT04955743Phase 2Results posted
• APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell CarcinomaCompletedNCT03502330Phase 1Results posted
• Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer (NSCLC)CompletedNCT02681549Phase 2Results posted
• Evaluating the Combination of MK-3475 and Sterotactic Body Radiotherapy in Patients With Metastatic Melanoma or NSCLCCompletedNCT02407171Phase 1/2Results posted
• Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is MetastaticCompletedNCT02094872Phase 2Results posted
• MK-3475 in Melanoma and NSCLC Patients With Brain MetastasesCompletedNCT02085070Phase 2Results posted
• Phase 2 Study of Neoadjuvant Vemurafenib in Melanoma Patients With Untreated Brain MetastasesCompletedNCT01781026Phase 2Results posted
• Programmed Cell Death 1 + Selected Cell Therapy With Durvalumab (MEDI4736) and Tremelimumab in Metastatic MelanomaWithdrawnNCT04223648Early Phase 1
• A Pilot Study Using Short-Term Cultured Anti-Tumor Autologous LymphocytesTerminatedNCT03526185Early Phase 1
• A Sunscreen Based on Bioadhesive NanoparticlesCompletedNCT02668536Phase 1
• A Study of Everolimus in Combination With Imatinib in Metastatic MelanomaTerminatedNCT00402662Phase 2
• Indium In 111 Pentetreotide in Treating Patients With Refractory CancerTerminatedNCT00002947Phase 1